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Background: Neuropathic pain is a difficult to treat disorder arising from central or peripheral nervous system
lesions. The etiology of neuropathic pain consists of several overlapping pathways converging into an exaggerated
pain state with symptoms such as allodynia and hyperalgesia. One of these pathways involves activation of spinal cord
microglia and astrocytes, which drive and maintain the inflammatory response following the lesion. These cells are a
potential target for drugs for neuropathic pain relief. In this current study, we investigated the dose-effect relationship
of the tissue protective peptide ARA 290, derived from the tertiary structure of erythropoietin, on allodynia and
concurrent spinal cord microglia and astrocytes.
Results: Following a spared nerve injury in rats, vehicle or ARA290 (administered in either one of 4 doses: 3, 10,
30 and 60 μg/kg) was administered on days 1, 3, 6, 8 and 10. ARA290 exerted a dose–response effect by
significantly reducing mechanical allodynia up to 20 weeks when compared to vehicle. The reduction of cold
allodynia was significant up to 20 weeks for the doses 3, 10, 30 and 60 μg/kg when compared to vehicle. The
effect 10 and 30 μg/kg ARA290 and vehicle on the microglia response (iba-1-immunoreactivity, iba-1-IR) and
astrocyte reaction (GFAP-immunoreactivity, GFAP-IR) was investigated in animals surviving 2 (group 1) or 20
(group 2) weeks following lesion or sham surgery. In group 1, significant microglia reactivity was observed in the
L5 segment of the spinal cord of animals treated with vehicle when compared to sham operated, while animals
treated with 10 or 30 μg/kg did not show a increase. In group 2, a more widespread and increased microglia
reactivity was observed for animals treated with 0 and 10 μg/kg when compared to sham operated animals,
indicated by involvement of more spinal cord segments and higher iba-1-IR. Animals treated with 30 μg/kg
did not show increased microglia reactivity. No difference in astrocyte reaction was observed.
Conclusions: The erythropoietin-analogue ARA290 dose-dependently reduced allodynia coupled to suppression
of the spinal microglia response, suggestive of a mechanistic link between ARA290-induced suppression of central
inflammation and relief of neuropathic pain symptoms.
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Neuropathic pain (NP) is a debilitating condition resulting
from lesions of the peripheral or central nervous system
with allodynia and hyperalgesia to mechanical or thermal
stimuli as main symptoms [1,2]. Treatment of NP is diffi-
cult and management of symptoms by pharmacological
(opioids, antidepressants or topical agents such as capsa-
icin) or non-pharmacological (physiotherapy) means is
often not adequate. The mechanisms underlying NP are
largely driven by peripheral and central inflammation
leading to peripheral and central sensitization. Periph-
erally, macrophages and T-cells are the main contribu-
tors to the inflammatory response [3,4]. In the central
nervous system astrocytes and microglia play a crucial
role in NP states after peripheral nerve injury by showing
altered numbers, morphology and activation states [5-11].
There is ample evidence for crosstalk between neurons
and glia cells leading to phenomena that underlie allodynia
and hyperalgesia [12]. In NP, glia become more abundant
and activated as a result of the induced release of prolifer-
ative molecules, such as fractalkine (chemokine (C-X3-C
motif) ligand 1; CX3CL1) and C-C motif chemoreceptor
ligand 2 (CCL2) released by neurons due to increased
afferent signaling [13-15], and local release and retro-
grade transport of TNF-α [16]. These glia cells are in-
volved in driving and maintaining the inflammatory
response, especially in the dorsal horn of the spinal cord,
by releasing inflammatory mediators, including TNF-α,
interleukins 1β and 6 and other signaling molecules for
periods that may extend over 2 weeks [17-20]. In
addition to the observations in experimental animal
studies, a case report of a patient with longstanding
complex regional pain syndrome describes increased
activation of astrocytes and microglia in the spinal
cord after autopsy when compared to patients without a
neuropathic pain condition [21]. These observations
strongly suggest that astrocytes and microglia serve as
potential targets for treatment of neuropathic pain. In-
deed, inhibition of activated microglia and astrocytes
reduces neuropathic pain symptoms in vivo [22-24].
We recently showed that the neuroprotective synthetic
11-amino acid erythropoietin (EPO) derivative ARA 290
produces effective and long-term pain relief following
peripheral nerve damage in the rat [25,26]. ARA 290
produces its effects via activation of the β-common-
receptor [25-27]. The β-common-receptor in conjunction
with the EPO receptor forms a heterocomplex (designated
the innate repair receptor, IRR), which becomes locally
up-regulated following tissue injury [28,29]. Its activation
initiates a local anti-inflammatory response, inhibition
of death signal and anti-apoptosis, thereby preventing
overt tissue damage. Additionally, activation of the IRR
also promotes tissue repair responses, including neurite
outgrowth in the nervous system [30]. In humans werecently showed that chronic ARA 290 administration
reduced pain symptoms and improved functionality in
patients with chronic neuropathic pain related to small
fiber neuropathy [31]. Various animal studies have shown
the tissue-protective effects of ARA 290, all related in
part to its anti-inflammatory effects. For example, ARA
290 improves survival following myocardial infarction,
reduces organ dysfunction in hemorrhagic shock and
suppresses development of atherosclerosis in hyperlip-
idemic rabbits [32-34].
In this study, we investigated the dose–response effect
of ARA 290 on mechanical and thermal allodynia in an
experimental rat model of chronic neuropathic pain (using
the spared nerve injury model in which two of the three
branches of the sciatic nerve are surgically cut). Next, to
better understand its mechanism of action, we assessed
whether ARA 290 has an anti-inflammatory effect at the
level of the spinal cord by visualizing spinal astrocyte and
microglia using immunohistochemistry. We hypothesize
that ARA 290 reduces the neuroinflammatory response in
chronic neuropathic pain.
Results
ARA 290 reduces mechanical and cold allodynia in a
dose-dependent manner
Mechanical allodynia
Following SNI, vehicle-treated animals progressively devel-
oped mechanical allodynia within 10 days with withdrawal
responses to the filament exerting the lowest possible force
(0.004 ± 0.0 grams). Sham operated animals showed no
decline in response threshold. Regardless of treatment,
all SNI groups differed significantly from sham operated
animals (p < 0.001 for all groups). The two-week treatment
with ARA 290 produced a lasting relief of tactile allodynia
(Figure 1A, treatment effect p < 0.001). Post hoc analysis
revealed significant effects for the 30 and 60 μg/kg
groups (30 μg/kg: p = 0.049 and 60 μg/kg: p < 0.001
versus vehicle). In contrast, the lower doses of ARA
290 did not produce significant relief of allodynia
(3 μg/kg: p = 0.825 and 10 μg/kg: p = 0.707 versus
vehicle). Comparing efficacy of treatment with ARA
290, a linear dose response relationship was observed
with an adjusted R2 of 0.56 (Figure 1B). Higher doses
of ARA 290 resulted in higher AUCs corresponding to
animals tolerating stimulation with filaments that exert a
greater force and hence less mechanical allodynia. Survival
analysis indicates that with higher dosages of ARA 290
relief from allodynia persists for longer time periods
(Figure 1C, Log-Rank p < 0.001).
Cold allodynia
Following SNI, vehicle-treated animals developed cold
allodynia within 7–14 days a mean score of 3.2 ± 0.2
(range 3 to 4). Sham operated animals showed no increase
Figure 1 Effect of ARA 290 on mechanical allodynia. A. Effect of spared nerve injury and treatment with vehicle or different doses of ARA 290
on mechanical allodynia. Animals were sham-operated (grey) or received spared nerve injury and 5 doses of vehicle (red), 3 μg/kg ARA 290 (yellow),
10 μg/kg ARA 290 (green), 30 μg/kg ARA 290 (marine blue), or 60 μg/kg ARA 290 (dark blue) administered on days 1, 3, 6, 8 and 10 post-surgery.
B. Correlation of ARA 290 treatment dose and the relief of mechanical allodynia, calculated by the difference in area under the curves (AUC) of the
mechanical allodynia response on day 1 vs. day 140. The adjusted R2 is 0.56. C. Survival analysis showing the mechanical allodynia-free proportion of
animals in time either sham-operated, or receiving spared nerve injury and treated with vehicle or different doses of ARA 290. Log-Rank p < 0.001.
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fered significantly from sham-operated animals (p < 0.001
for all groups). Animals treated with ARA 290 showed
a dose-dependent relief of allodynia (Figure 2A, treat-
ment effect p < 0.001). Post hoc analysis showed that at
all doses allodynia was significantly less compared to
vehicle (p < 0.001). A linear ARA 290 dose–response
relationship was observed with an adjusted R2 of 0.78
(Figure 2B). Higher doses of ARA 290 resulted in lower
AUCs corresponding to animals responding less vigorously
to the application of acetone and hence less thermal
allodynia. Survival analysis indicates that a more persisting
effect was obtained at higher ARA 290 doses (Figure 2C,
Log-Rank p < 0.001).
ARA 290 prevents the increase of iba-1-immunoreactivity
in the dorsal horn
In Figure 3, representative overviews are given from the
spinal cords of animals after 2 weeks of survival that
received SNI with vehicle (Figure 3A), SNI with 30 μg/kg
ARA 290 (Figure 3B) or sham surgery without treatmentFigure 2 Effect of ARA 290 on cold allodynia. A. Effect of spared nerve
cold allodynia scores. Animals were sham-operated (grey) or received spare
10 μg/kg ARA 290 (green), 30 μg/kg ARA 290 (marine blue), or 60 μg/kg A
(for each treatment p < 0.0001 compared to vehicle). Scoring of cold allody
treatment dose and the relief of cold allodynia, calculated by the difference
vs. day 140. The adjusted R2 is 0.78. C. Survival analysis showing the cold al
receiving spared nerve injury and treated with vehicle or different doses of(Figure 3C). There was an apparent increased iba-1-
immunoreactivity (iba-1-IR) on the side of the injury that
seemed more pronounced in the 0 μg/kg treated group
when compared to the 30 μg/kg group. The dorsal horns
of animals that received SNI and treatment with vehicle
(Figure 3D), 30 μg/kg ARA 290 (Figure 3E) or sham
surgery without treatment (Figure 3F) showed increased
iba-1-IR in the dorsal horn which was more pronounced
in vehicle-treated animals. High power magnifications of
individual microglia from the dorsal horns of animals that
received SNI and treatment with vehicle (Figure 3G),
30 μg/kg ARA 290 (Figure 3H) or sham surgery without
treatment (Figure 3I). Microglia from the vehicle-treated
group showed an activated phenotype with an amoeboid
shape and retracted rami, whereas microglia from the
30 μg/kg treatment group and sham surgery group
showed a resting phenotype with a stretched soma and
rami. For further analysis, computerized calculation of
the amount of immunoreactivity was performed.
Representative images of recorded photomicrographs
of iba-1-IR in lumbar dorsal horns L1 to L6 of animalsinjury and treatment with vehicle or different doses of ARA 290 on
d nerve injury and 5 doses of vehicle (red), 3 μg/kg ARA 290 (yellow),
RA 290 (dark blue) administered on days 1, 3, 6, 8 and 10 post-surgery
nia is described in the Methods Section. B. Correlation of ARA 290
in area under the curves (AUC) of the cold allodynia score on day 1
lodynia-free proportion of animals in time either sham-operated, or
ARA 290. Log-Rank p < 0.001.
Figure 3 Effect of ARA 290 on Iba-1 immunoreactivity in the L5 spinal cord segment of animals 2 weeks after spared nerve injury.
Representative photomicrographs of Iba-1 immunoreactivity (green) in the L5 spinal cord segment of animals 2 weeks after spared nerve injury
(SNI). (A-C) Low power magnifications, (D-F) detailed images of (A-C) as indicated by the white rectangles, and (G-I) high power magnifications
of the spinal cord of animals that underwent: A, D and G. SNI and vehicle treatment, B, E and H. SNI and treatment with 30 μg/kg ARA 290,
C, F and I. sham surgery without treatment. The left-hand side of the photomicrographs represents the ipsilateral side of the animal, innervating
the site of spared nerve injury.
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treated with the various ARA 290 doses are given in
Figure 4A and B with high power magnifications of
microglia cells presented in the inserts. For group 1
(2 weeks post injury), microglia in the L5 segment of the
vehicle treatment group showed an activated phenotype,
whereas the microglia in other panels show a resting
phenotype. Iba-1-IR was increased in the L5 segment
following vehicle treatment only (Figure 5A, p < 0.05
versus sham). Irrespective of treatment, no increase in
reactivity was observed in any of the other segments. In
contrast, in group 2 (20 weeks post injury), iba-1-IR had
spread both cranially and caudally to multiple spinal cord
segments in vehicle-treated animals (Figure 4B) with
significantly increased iba-1-IR in segments L2 to L5
(p < 0.05 vs. sham). As shown in the inserts of Figure 4B,
microglia in the L1-L6 segments of the vehicle and
10 μg/kg treatment groups showed an activated pheno-
type, whereas the microglia in the 30 μg/kg and sham
groups showed a resting phenotype. In Groups 1 and 2,
treatment with 30 μg/kg ARA 290 prevented an in-
crease in iba-1-IR as shown by the absence of iba-1-IR
in all segments (Figure 5A and B; 30 μg/kg: ns vs.
sham, p < 0.05 vs. vehicle at segments L2 to L4). In
Group 2, treatment with 10 μg/kg of ARA 290 did not
decrease iba-1-IR relative to vehicle-treated animals
(Figure 5B; ns vs. vehicle, p < 0.05 vs. 30 μg/kg at segments
L2-L4).SNI does not increase GFAP-immunoreactivity in the
dorsal horn
SNI did not induce an astrocytic response in vehicle-
treated animals relative to sham-operated rats for spinal
cord segments L1-L6 at either 2 weeks or 20 weeks post in-
jury (Figures 6 and 7). No effect of treatment was observed.
Discussion
The main findings of this study are: (1) The spared nerve
injury model caused a rapid and long-lasting neuropathy
with mechanical and cold allodynia; (2) ARA 290 pro-
duced dose-dependent relief of both mechanical and cold
allodynia; (3) A spreading microglia response (i.e. iba-1-IR
and phenotype) was apparent from L5 at week 2 following
nerve damage to L2-6 at week 20; (4) No effect of nerve
injury on the astrocyte response was observed at weeks
2 and 20 following nerve damage; and (5) ARA 290
suppressed iba-1R in a dose dependent manner.
Neuropathic pain in animals (due to experimental nerve
damage) and humans (due to sarcoidosis or diabetes melli-
tus type 2) responds well to treatment with ARA 290, in
that it produces relief of spontaneous pain (humans) and
allodynia (humans and animals) [25,26,31,35]. Studies in
mice that lack the β-common-receptor show further that
ARA 290 is without behavioral effect (ie. allodynia is not
relieved by ARA 290), implicating this receptor as site
of action of ARA 290 [25,26]. The β-common-receptor
forms a heterocomplex together with EPO receptor and it
Figure 4 (See legend on next page.)
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Figure 4 Effect of ARA 290 on Iba-1 immunoreactivity on L1-L6 spinal cord segments of animals 2 and 20 weeks after spared nerve
injury. A. Representative photomicrographs of Iba-1 immunoreactivity (green) in the lumbar dorsal horns of animals 2 weeks after spared nerve
injury (SNI). Animals were either treated with vehicle (upper row), 10 μg/kg ARA 290 (second row) or 30 μg/kg ARA 290 (third row). The bottom
row represents sham-operated animals without treatment. In each column, the Iba-1 immunoreactivity signal at different lumbar spinal cord levels
(L1-L6) is shown. Inserts show higher magnifications of the photomicrographs. B. Representative photomicrographs of Iba-1 immunoreactivity (green)
in the lumbar dorsal horns of animals 20 weeks after spared nerve injury (SNI). Animals were either treated with vehicle (upper row), 10 μg/kg ARA 290
(second row) or 30 μg/kg ARA 290 (third row). The bottom row represents sham-operated animals without treatment. In each column, the Iba-1
immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is shown. Inserts show higher magnifications of the photomicrographs.
Swartjes et al. Molecular Pain 2014, 10:13 Page 6 of 12
http://www.molecularpain.com/content/10/1/13is believed that this receptor complex, which we designate
the innate repair receptor (IRR), is the molecular site of
action of both EPO and ARA 290 [27,29,36]. Exogenous
EPO, similar to ARA 290, reverses allodynia and reduces
neuronal apoptosis and proinflammatory cytokine pro-
duction, neuronal regeneration and the release of anti-
inflammatory cytokines [28]. We do not use EPO in our
studies as, in contrast to ARA 290, it comes with severe
side effects including enhanced hematopoiesis and car-
diovascular complications (eg. hypertension, thrombosis,
myocardial infarction). In common with previous studies
[25,26], we show here that ARA 290 has effective and
prolonged (up to 20 weeks) anti-allodynic effects.
There is ample evidence that peripheral nerve injury
results in a strong spinal inflammatory response [17].
For example, we previously showed in mice that surgical
damage to the sciatic nerve causes the increase of expres-
sion of pro-inflammatory markers including iba-1 mRNA,
GFAP mRNA and CCL2 mRNA, within 7 days following
nerve damage [26]. CCL2 plays an important role in the
invasion of monocytes from peripheral blood as well as
resident macrophages towards the spinal cord lesion site
following peripheral nerve damage. In our current study
the inflammatory response following SNI was apparent
from the increase in iba-1-IR. The iba-1-IR response
showed a marked expansion from level L5 in week 2
following SNI, to 5 adjoining segments, L2 to L6, at
week 20. In addition to the spreading of iba-1-IR toFigure 5 Effect of ARA 290 on Iba-1 immunoreactivity after spared ne
(percentage of immunostained area) in sections of different lumbar spinal cor
after sham-operation (grey), spared nerve injury and vehicle-treated (red), spar
nerve injury and treatment with 30 μg/kg ARA 290 (marine blue). At 2 weeks
treatment only (grey box p < 0.05 vs. sham). At 20 weeks post injury (B), vehic
at segments L2-L4 (grey boxes). Data are mean ± SEM.multiple segments, the intensity of the response also
increased over time as shown by a higher degree of iba-
1-IR and phenotypic signs of activation. We are the
first to show this spreading inflammatory response in
the spared nerve injury model of neuropathic pain.
Similar observations were made earlier in experimental
models of spinal cord injury and nerve root avulsion
[37,38]. Previous reports of glial response following
peripheral nerve injury showed that the response area
is confined to the spinal cord segments innervated by
the damaged nerve [39,40]. However, these responses
were measured within a 2-week time frame. This is in
agreement with our observation of lack of spreading at
week 2. Caudal and cranial expanding inflammation, as
observed here, may explain the increase in severity of
NP symptoms over time and development of symptoms
in areas of the body not innervated by the damaged
nerve [41]. Similarly, various experimental reports indi-
cate that the inflammatory responses may spread to
contralateral spinal cord areas [8,42]. In this study we
did not quantify contralateral inflammation. Our data do
suggest that time is an important factor in the spreading
of the microglia response.
Iba-1-IR reflects microglia activation in addition to
localization and morphology. Our data show increased
iba-1-IR after SNI, which is dose-dependently and long-
term reduced by ARA 290 treatment coupled to a dose-
dependent and long-term reduction of mechanical andrve injury. Quantification graphs showing Iba-1 immunoreactivity
d levels (L1-L6) from animals 2 weeks (panel A) or 20 weeks (panel B)
ed nerve injury and treatment with 10 μg/kg ARA 290 (green), or spared
post injury (A), Iba-1-IR was increased in the L5 segment following vehicle
le p < 0.05 vs. sham at segments L2-L5) and 10 μg/kg: p < 0.05 vs. sham
Figure 6 (See legend on next page.)
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Figure 6 Effect of ARA 290 on GFAP immunoreactivity on L1-L6 spinal cord segments of animals 2 and 20 weeks after spared nerve
injury. A. Representative photomicrographs of GFAP immunoreactivity (green) in the lumbar dorsal horns of animals 2 weeks after spared nerve
injury (SNI). Animals were either treated with vehicle (upper row), 10 μg/kg ARA 290 (second row) or 30 μg/kg ARA 290 (third row). The bottom
row represents sham-operated animals without treatment. In each column, the GFAP immunoreactivity signal at different lumbar spinal cord levels
(L1-L6) is shown. Inserts show higher magnifications of the photomicrographs. B. Representative photomicrographs of GFAP immunoreactivity (green)
in the lumbar dorsal horns of animals 20 weeks after spared nerve injury (SNI). Animals were either treated with vehicle (upper row), 10 μg/kg ARA 290
(second row) or 30 μg/kg ARA 290 (third row). The bottom row represents sham-operated animals without treatment. In each column, the GFAP
immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is shown. Inserts show higher magnifications of the photomicrographs.
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modulatory effect of ARA 290. We argue that ARA 290
initiates a cascade of events involving several transduction
factors of which activation of the IRR is the first step that
eventually silences or reduces the inflammatory process
[29,36]. Since the activation or recruitment of microglia is
largely mediated through the local production of CCL2
[43,44], a possible scenario is that ARA 290 reduces the
release of CCL2 via activation of the IRR on neuronal
and immune cells [26]. However, both at 2 and 20 weeks
after SNI and ARA 290 treatment, relief of allodynia
was not complete, indicating that the central response to
peripheral nerve damage involves multiple systems includ-
ing neuroinflammation and probably also up-regulation
of excitatory pathways and synaptic plastic changes. Of
interest is that ARA 290 treatment causes a reduction
in NMDA mRNA (subunits NR1, NR2A and NR2B) in
SNI animals, suggestive of an additional role, apart from
immune-modulation, for ARA 290 in the treatment of
neuropathic pain by suppression of excitatory glutamater-
gic activity [26].
In contrast to a markedly increased iba-1-IR after SNI,
no change in GFAP-IR or astrocytic phenotype (ie. acti-
vation) was observed in animals with an SNI treated with
vehicle after 2 and 20 weeks of lesion. This observation
stands in contrast with reports describing involvement
of astrocytes adjacent to microglia in NP [5,7,10,45,46].
The absence of astrocytosis in our SNI model may be
explained by a time-limited astrocyte response (ie. < 2 weeks
or between 2–20 weeks). The involvement of astrocytesFigure 7 Effect of ARA 290 on GFAP immunoreactivity after spared n
(percentage of immunostained area) in sections of different lumbar spinal cor
after sham-operation (grey), spared nerve injury and vehicle-treated (red), spar
nerve injury and treatment with 30 μg/kg ARA 290 (marine). Data are mean ±following peripheral nerve injury reported in the literature
varies with some studies showing a relatively short-lived
increase in GFAP-IR [7], while others show an increase in
GFAP-IR after 14 days that was still present after 150 days
[5]. Further studies using more dense observations over
time are required to get a reliable indication of the kinetics
of the astrocyte response to peripheral nerve damage.
We have argued that the spinal cord is the predomin-
ant site of action of ARA 290 following peripheral nerve
damage. Indeed, there is ample evidence that peripheral
nerve injury activates an innate immune response activated
in the spinal cord [5-11]. Furthermore, a complete block of
the peripheral nerve with local anesthetics will not prevent
central inflammation following peripheral nerve damage
but only delays the development of pain, suggestive of a
predominant central effect [47,48]. Still, at this point we
cannot exclude an additional peripheral effect of ARA
290. Indeed, EPO specifically reduces axonal TNF-α in
Schwann cells after peripheral nerve injury, resulting in
attenuation of NP symptoms [49]. Hence, in addition to
a central nervous system effect, modulation of the per-
ipheral nerve immune response could also be part of
the mechanism of action of ARA 290, but these specific
effects remain to be investigated.
Conclusions
In conclusion, in the spared nerve injury model, we
show that the erythropoietin-analogue ARA 290 dose-
dependently reduces allodynia coupled to suppression of
the spinal microglia response, suggestive of a mechanisticerve injury. Quantification graphs showing GFAP immunoreactivity
d levels (L1-L6) from animals 2 weeks (panel A) or 20 weeks (panel B)
ed nerve injury and treatment with 10 μg/kg ARA 290 (green), or spared
SEM.
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inflammation and relief of neuropathic pain symptoms.
Methods
Animals
The experimental protocol was approved by the Animal
Ethics Committee (Dierethische Commissie) of the Leiden
University Medical Center, Leiden, The Netherlands and
the Animal Care and Use Review Office (ACURO) of the
United States Army Medical Department Medical Research
and Materiel Command. All experiments were performed
in accordance to the guide lines of the International Associ-
ation for the Study of Pain [50]. Forty-two, eight-week-old,
female Sprague–Dawley rats (Charles River, Maastricht,
The Netherlands) weighing 200 to 260 grams were used
in this study. Animals were housed two per cage in in-
dividually ventilated cages for the duration of the entire
experimental period under standard laboratory conditions
with water and food ad libitum and a 12 h-12 h light/dark
cycle. At the end of the studies the animals were anes-
thetized and euthanized by exsanguination under 6%
sevoflurane anesthesia, perfuse-fixed with 100 ml ice-cold
heparinized saline followed by 150 ml 4% paraformalde-
hyde for tissue extraction.
Neuropathic pain model
Chronic neuropathic pain was induced in 34 rats by
spared nerve injury (SNI) [25]. Animals were anesthetized
with 6% sevoflurane induction and 3% maintenance. A
small incision was made in the lateral surface of the left
thigh of the animal, exposing the muscles. The trifurcation
of the sciatic nerve was revealed by blunt preparation
between the two heads of the biceps femoris muscle.
Next, the tibial and common peroneal nerves were tightly
ligated with 5–0 silk in rats and cut to remove 2–4 mm
of the distal nerve. The sural nerve was left intact. In
order to prevent spontaneous nerve reconnection, the
transected nerves were displaced. During the surgical
procedure, great care was taken not to stretch or touch the
sciatic or sural nerves. The wound was closed in one layer
with 4–0 ethilon and a single dose of 0.01 mg/kg buprenor-
phine was administered to relieve acute postoperative pain.
Eight animals received a sham operation where the
nerve was exposed, but not ligated and transected. The
wound was closed in one layer with 4–0 ethilon sutures
and a single dose of 0.01 mg/kg buprenorphine was
administered for the relief of acute postoperative pain.
After surgery, animals were allowed to recover with body
temperature maintained at 38°C for 1 h before being
transferred to a cage with fresh saw dust.
Treatment
The experimental drug ARA 290 was dissolved in phos-
phate buffered saline (PBS) to obtain a stock solution,aliquoted and stored at 4°C until use. Prior to injection,
the stock solution of was diluted in PBS to yield the
desired dose in 200 μl. Following surgery, 34 animals
were treated on days 1, 3, 6, 8 and 10 post-surgery. All
injections were administered intraperitoneally. Nine of
the animals were sacrificed after the 2-week treatment
period (Group 1); twenty-five animals were followed
for another 18-weeks following treatment and then
sacrificed (Group 2). Group 1 animals were randomly
allocated to one of the following treatment groups: 0
(= vehicle; PBS), 10, 30 μg/kg (n = 3/group). Group 2
animals were randomly allocated to one of the following
treatment groups: 0 (= vehicle; PBS), 3, 10, 30, 60 μg/kg
ARA 290 (n = 5/group). Three animals in Group 1 and five
in Group 2 received sham surgery and were not treated
(ie. sham controls).Neuropathic pain assay
Allodynia was assessed prior to surgery (baseline values),
at days 1, 3, 6, 8 and 10 during the treatment period,
and during follow up from day 14 on at 1-week intervals.
The test site was the plantar surface of the injured hind
paw. The animals were placed in a transparent cage on an
elevated wire mesh floor and were allowed to habituate for
at least 10 minutes before testing for mechanical allodynia,
followed by thermal allodynia after a short interval to
allow recovery from the previous test. When testing
coincided with a treatment day, testing was performed
prior to administration of ARA290 or vehicle.
Mechanical allodynia was tested with the use of von
Frey hairs (Semmes-Weinstein Monofilaments, North
Coast Medical Inc., San Jose, CA) with increasing stiff-
ness (0.004 – 300 g) causing incremental forces to be
exerted on the plantar surface of the injured hind paw.
The hairs were applied 10 times at a frequency of 1 Hz
to slightly different loci within the test area to avoid
sensitization due to repetition. The force necessary to
evoke a pain reflex by a brisk paw withdrawal was
recorded and no further filaments were applied to the
paw that showed a response. All measurements were
obtained in duplex with a 1-minute interval between
the tests and then averaged.
Cold allodynia was tested by using the acetone test.
Fifty microliters of acetone was sprayed on the plantar
surface of the hind paw. The response of the animal was
recorded using the following classification: 0 = no with-
drawal, 1 = startle response lasting less than 1 s, 2 =
withdrawal lasting between 1 and 5 s, 3 = withdrawal
lasting between 5 and 30 s (with or without paw licking)
and 4 = withdrawal lasting longer than 30 s (with or
without licking and repeated shaking). All measurements
were obtained in duplex with a 1-min interval between
the tests and then averaged.
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After perfuse-fixing the animals, the lumbar spinal cord
was extracted and post-fixed in 4% paraformaldehyde
for 24 h. After post-fixation, the tissues were cryopro-
tected for 72 h in 30% sucrose before embedding them
in TissueTek (Sakura FineTek, Alphen a/d Rijn, The
Netherlands). The extracted lumbar spinal cord was
sectioned transversally at a freezing microtome at −20°C
to obtain serially sectioned 20 μm sections. Every 10th
section was mounted on a Superfrost + slide (Menzel
Gläser, Braunschweig, Germany) and stored at −80°C prior
to staining. For immunohistological staining, sections for
all animals of both time points were stained in one run
for each antibody to reduce variability between stainings.
The sections were retrieved from the freezer and allowed
to thaw before blocking for 1 h with 10% goat serum
(Invitrogen, Auckland, New Zealand) with 0.4% Triton
X-100 (Sigma-Aldrich, St. Louis, USA). Sections were
stained overnight at 4°C for microglia with 1 μg/ml rabbit-
anti-Iba-1 (Wako Chemicals GmbH, Neuss, Germany) or
astrocytes with 1:200 rabbit-anti-GFAP (Dako, Heverlee,
Belgium) in 3% normal goat serum with 0.4% Triton
X-100. After 3 washings in PBS, the slides were incubated
for 3 h at room temperature with 1:500 goat-anti-
rabbit-Alexa488 (Invitrogen, Eugene, USA) as a second-
ary antibody in 3% normal goat serum with 0.4% Triton
X-100. After incubation, slides were washed 3 times
with PBS and Vectashield (Vector Laboratories Inc.,
Burlingame, USA) as an anti-fading agent was applied.
Lastly, the slides were cover slipped and sealed with nail
polish. Standardized microphotographs of the dorsal horn
were taken with a Leica M5500 fluorescence microscope
(Leica Microsystems, Rijswijk, The Netherlands). During
photography, the spinal cord segment of the image was
determined with a spinal cord histology atlas on the basis
of white matter to grey matter ratio, ventral horn morph-
ology and dorsal horn morphology and documented for
classification during analysis [51]. The photomicrographs
were analyzed using ImageJ (NIH, Bethesda, MD, USA).
Image analysis
First, images were screened for quality by assessing if
the dorsal horn was completely visible, without folds or
significant damage. Images that did not meet these criteria
were not analyzed (on average 5.3% per group). Next,
the remaining 8-bit grey scale images were thresholded
using the auto threshold function of ImageJ to create
dichromatic images required for analysis of the percentage
covered with immunoreactive cells. This function object-
ively separates signal from noise and no adjustments
for background, brightness or contrast were performed.
Obtained values were averaged per spinal cord segment
for each animal; the images given represent these average
responses.Statistics
Allodynia
Behavioral data for effects on tactile and cold allodynia
were analyzed by 2-way analysis of variance with post hoc
Student-Newman-Keuls comparisons for multiple testing.
The effect of dose-dependency was analyzed by calculating
the area under the curve with the trapezoid rule and curve
fitting the data using a linear function. Log-Rank survival
curves were created to determine the duration of allodynia
relief by ARA 290 treatment. End-points were defined as
reaching the maximum amount of measurable allodynia
(reaching the 0.004 g filament or reaching a score of 4
in the acetone test). Holm-Sidak post hoc analysis for
multiple comparisons was performed.
Microscopy
Spinal cord microscopy data were analyzed per segment
by two-way analysis of variance with post hoc Student-
Newman-Keuls comparisons for multiple testing.
All data are presented as mean ± SEM unless otherwise
stated. p-values < 0.05 were considered significant.
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